Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer

被引：0
|
作者：
David, Goldstein [1 ]
Daniel, Von Hoff [2 ]
Chiorean, E. [3 ]
Michele, Reni [4 ]
Josep, Tabernero [5 ]
Ramesh, Ramanathan [6 ]
Julia, Wilkerson [7 ]
Marc, Botteman [7 ]
Abdalla, Aly [7 ]
Sandra, Margunato-Debay [8 ]
Brian, Lu [8 ]
Chrystal, Louis [8 ]
Markus, Renschler [8 ]
Desmond, McGovern [9 ]
Chee, Lee [10 ]
机构：
[1] Prince Wales Hosp, Sydney, NSW, Australia
[2] TGen & HonorHlth, Phoenix, AZ USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Osped San Raffaele, Milan, Italy
[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[6] Scottsdale Healthcare TGen, Scottsdale, AZ USA
[7] Pharmerit Int, Bethesda, MD USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene, Stockley Pk, England
[10] Univ Sydney, NHMRC Clin Trial Ctr, Camperdown, Tyne & Wear, Scotland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 017
引用
收藏
页数：3
相关论文
共 50 条
  • [21] An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) plus gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
    Lazzaro, Carlo
    Barone, Carlo
    Caprioni, Francesco
    Cascinu, Stefano
    Falcone, Alfredo
    Maiello, Evaristo
    Milella, Michele
    Pinto, Carmine
    Reni, Michele
    Tortora, Giampaolo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (04) : 435 - 446
  • [22] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Von Hoff, Daniel D.
    Tabernero, Josep
    El-Maraghi, Robert
    Ma, Wen Wee
    Reni, Michele
    Harris, Marion
    Whorf, Robert
    Liu, Helen
    Li, Jack Shiansong
    Manax, Victoria
    Romano, Alfredo
    Lu, Brian
    Goldstein, David
    BRITISH JOURNAL OF CANCER, 2016, 115 (02) : 188 - 194
  • [23] Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
    Barrera, Ivan
    Filimon, Sabin Dragos
    Meng, Jassy
    Kavan, Tomas
    Rho, Young Soo
    Batist, Gerald
    Kavan, Petr
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew V.
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    GASTROENTEROLOGY, 2015, 148 (04) : S944 - S944
  • [25] Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience
    Lo Re, Giovanni
    Santeufemia, Davide A.
    Foltran, Luisa
    Bidoli, Ettore
    Basso, Stefano M. M.
    Lumachi, Franco
    ONCOTARGET, 2015, 6 (10) : 8255 - 8260
  • [26] SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
    Hidalgo, Manuel
    Plaza, Carlos
    Musteanu, Monica
    Illei, Peter
    Brachmann, Carrie B.
    Heise, Carla
    Pierce, Daniel
    Lopez-Casas, Pedro P.
    Menendez, Camino
    Tabernero, Josep
    Romano, Alfredo
    Wei, Xinyu
    Lopez-Rios, Fernando
    Von Hoff, Daniel D.
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4811 - 4818
  • [27] Maintenance treatment with gemcitabine after gemcitabine plus Nab-paclitaxel in advanced pancreatic cancer
    Kodama, Tomoko
    Nakazawa, Junichi
    Kawahira, Masahiro
    Ymasuji, Akihiro
    Iwashita, Yuji
    Hori, Takeshi
    Kawahira, Machiko
    Arima, Shiho
    Tubouchi, Hirohito
    Ido, Akio
    ANNALS OF ONCOLOGY, 2022, 33 : S484 - S484
  • [28] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [29] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
    Dorman, Klara
    Boeck, Stefan
    Caca, Karel
    Reichert, Maximilian
    Ettrich, Thomas J.
    Oettle, Helmut
    Waidmann, Oliver
    Modest, Dominik P.
    Mueller, Lothar
    Michl, Patrick
    Kanzler, Stephan
    Pink, Daniel
    Reinacher-Schick, Anke
    Geissler, Michael
    Pelz, Henning
    Kunzmann, Volker
    Held, Swantje
    Schichtl, Thomas
    Heinemann, Volker
    Kullmann, Frank
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (10): : 935 - 943
  • [30] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
12345